Individuals with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia (HHT) commonly have low oxygen saturations and anaemia, two parameters generally used to indicate medical fitness to fly. Using a retrospective questionnaire-based study, the authors examined inflight complications and predictors in 145 HHT patients (96 with PAVMs) who reported 3950 flights, totalling 18 943 flight hours. Dyspnoea and thrombotic complications were less common than expected, and could not be predicted from sea level oxygen saturations or haemoglobin concentrations. Nosebleeds that can bar individuals from boarding a flight occurred in 13.6% (11.5% to 15.8%) of longhaul flights. The findings should influence preflight advice.
Individuals with pulmonary arteriovenous malformations (PAVMs) 1 and hereditary haemorrhagic telangiectasia (HHT) 2 commonly have low oxygen saturations and anaemia, parameters that are used in the general population to indicate medical fitness to fly 3e5 (and online supplementary references). There are very limited published data on flight tolerance for HHT/PAVM patients.
Using the retrospective study methodology reported in full in the online supplementary material, we received 159 replies from 308 questionnaires sent out to individuals with definite HHT (response rate 51.6%). The average age at the time of reply was 55 years (range 18e90), 12 respondents had not flown and two (pilot and cabin crew) reported more than 10 000 flights. The remaining 145 HHT-affected respondents (96 (66%) with PAVMs) reported 18 943 flight hours over 3950 flights (online supplementary table 1).
The majority (111/145; 77% (95% CI 69.6% to 83.5%)) reported no in-flight or postflight complications. Six (4.1% (0.86% to 7.4%)) reported dyspnoea, two had a deep vein thrombosis and one suffered an ischaemic stroke while flying. The most common in-flight complications were HHTrelated nosebleeds (epistaxis). Complications were more frequent during long-haul flights. Many participants listed flights over several decades, but none reported an increase in the frequency or severity of complications as they got older.
For participants with PAVMs who had not reported in-flight dyspnoea, there was a wide range in arterial oxygen saturation (SaO 2 ) levels (figure 1A). There was no difference in median SaO 2 between those who reported in-flight dyspnoea and those who did not (figure 1B). Flights where dyspnoea was reported did not correspond to times when SaO 2 were lowest for that particular individual ( figure 1C) . Similarly, there appeared to be no relationship between dyspnoea and either haemoglobin or serum iron (online supplementary figure 1 ). There was also no relationship between thrombotic complications and oxygen saturations/haemoglobin (online supplementary figure 2) or between in-flight nosebleeds and basal nosebleeds frequency (if at least once per month) or haemoglobin (online supplementary figure 3 ).
In conclusion, and as discussed in more detail in the online supplementary material, the principal findings of this study were that flying appears safe for the majority of individuals with PAVMs and HHT despite abnormal oxygen saturations and haemoglobin concentrations. With the exception of nosebleeds, complications, when they occurred, were usually self-limiting. It was difficult to predict who will experience complications, with the best predictor appearing to be previous flight experience. The findings are surprising, and raise difficulties in recommendations for in-flight oxygen and prophylaxis of venous thromboemboli.
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Lee et al should be commended for showing that non-invasive haemodynamic monitoring using inert gas rebreathing (IGR) might be a valuable tool to detect treatment response in patients with precapillary pulmonary hypertension (PH). 1 Even under resting conditions, haemodynamic parameters may be more sensitive than the 6-minute walk distance. This is especially interesting as it may facilitate frequent therapy monitoring. Although pulmonary blood flow (PBF) equals cardiac output (CO) in the absence of relevant intrapulmonary shunting, it should be noted that a reliable shunt correction algorithm based on the haemoglobin value has already been implemented in the IGR device. 2 Since using solely PBF significantly increased the measurement bias as compared with the non-invasive gold standard of cardiac MRI, shunt correction should always be applied. A fixed haemoglobin concentration of 14.0 g/dl can be used, if the exact value is not known. 3 This seems to be especially important as pulmonary shunting might be altered in PH. In serial measurements, therapeutic effects and changes in CO may also be due to shunting. This may remain undetected when solely measuring PBF. In analogy to the 6-minute walk distance, IGR measurements require active collaboration, which may limit their application in patients with advanced disease, high WHO functional class or lack of motivation. In these cases, other techniques of measuring CO such as impedance cardiography or continuous-wave Doppler may become potentially valuable, although they are not sufficiently applicable under exercise conditions. There is a rather large variation when compared with IGR or cardiac MRI; however, the reproducibility is high, which is of tremendous importance in serial measurements. 4e6 Although the overall PBF values in the study at hand were between 3.1 and 6.5 l/min, we would like to mention that there is a significantly worse agreement for IGR in large heterogeneous patient collectives at extreme CO states represented by values between 2e4 and 6.4e9.6 l/min, respectively. 7 However, this seems to be negligible considering the aims of the study as the reproducibility is not affected. We agree that based on the very promising findings of Lee et al, non-invasive haemodynamic measurements in PH justify further studies to improve and monitor specific therapy. IGR seems to be perfectly suitable for measurements during exercise as it is the only non-invasive device to be used under these conditions. 
